Floatz logo

ANTI-CD30 MONOCLONAL ANTIBODY XMAB2513

Hodgkins Lymphoma

Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

150 Active assets in the Hodgkins Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
CARMUSTINE
VIVUS LLC
Phase 2BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

ANTI-CD30 MONOCLONAL ANTIBODY XMAB2513 is also rated in:

anaplastic large cell lymphomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →